Pfizer: Alopecia Areata trials

The registry lists 17 Alopecia Areata studies with Pfizer as lead sponsor. 5 are open to participants now and 6 have results posted.

Phase 1 1Phase 2 4Phase 3 6No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia AreataRecruitingNCT07733765Phase 3
• A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.RecruitingNCT07152119
• A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.RecruitingNCT07029828Phase 3
• A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia AreataRecruitingNCT06873945Phase 3
• Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)AvailableNCT05522556
• A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of AgeCompletedNCT05650333Phase 1Results posted
• Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia AreataCompletedNCT04556734Phase 2Results posted
• PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATATerminatedNCT04517864Phase 2Results posted
• Long-Term PF-06651600 for the Treatment of Alopecia AreataCompletedNCT04006457Phase 3Results posted
• PF-06651600 for the Treatment of Alopecia AreataCompletedNCT03732807Phase 2/3Results posted
• Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia AreataCompletedNCT02974868Phase 2Results posted
• Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims DataActive, not recruitingNCT07821216
• Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the USCompletedNCT07226531
• A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world SettingsCompletedNCT07200128
• A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataActive, not recruitingNCT07029711Phase 3
• Characterization And Clinical Outcomes of AA Patients Treated With RitlecitinibActive, not recruitingNCT06531109
• Litfulo Capsules Special InvestigationActive, not recruitingNCT06279221